Skip to content
Bored Studies
RecruitingPhase 2

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NewAmsterdam Pharma · NCT07794670

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 55–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
400
US sites recruiting
1
Study start
September 2026
Record last updated
September 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Being studied: Obicetrapib 10 mg; Matching placebo tablets

Conditions: Preclinical Alzheimer's Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • participants with preclinical AD

Exclusion Criteria

  • APOE genotype not meeting protocol-defined eligibility criteria

Recruiting US locations

  • K2 Medical Research

    Nashville, TN 37204

    Site contact: Victoria Marsh · 615-208-K2K2 (5252) · victoria.marsh@k2med.com

All neurology studies in Tennessee →
Randomized Study to Evaluate the Effect of Obicetrapib in… (NCT07794670) | Bored Studies